Investment
Features
FeesSafety
Academy
More
Pluang+

JBS shows strong Q4 revenue growth and solid financials, maintaining a 'BUY' rating with $18.2 target.

Analyst Insights
27 Mar 2026
Seeking Alpha
View Source
Bullish
pluang ai news

JBS N.V., a global leader in protein, reported robust revenue growth in Q4 2025, driven by its omniprotein model and expansion in EMEA and legacy markets. The company holds a strong balance sheet with $8.2 billion in cash and reduced net debt, supporting ongoing capital expenditures and strategic initiatives. Despite sector volatility, the analyst reiterates a 'BUY' rating with an $18.2 per share price target, highlighting attractive risk/reward and upside potential compared to peers. Investors should be aware of inherent volatility and conduct their own due diligence before investing.

More News (TSN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App